Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

PDF  |  How to cite

Oncotarget. 2020; 11:1289-1289. https://doi.org/10.18632/oncotarget.27407

Metrics: PDF 1436 views  |   ?  

Sunkyu Kim1, Ralph Tiedt2, Alice Loo1, Thomas Horn1, Scott Delach1, Steven Kovats1, Kristy Haas1, Barbara Schacher Engstler2, Alexander Cao1, Maria Pinzon-Ortiz1, Iain Mulford1, Michael G. Acker1, Rajiv Chopra3, Christopher Brain4, Emmanuelle di Tomaso1, William R. Sellers1 and Giordano Caponigro1

1 Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA
2 Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland, USA
3 Novartis Institutes for BioMedical Research, Chemical Biology & Therapeutics, Cambridge, MA, USA
4 Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Cambridge, MA, USA

Published: April 07, 2020

This article has been corrected: In Table 1, a unit of measurement is displayed incorrectly. “μM” is used instead of “nM”. The corrected Table 1 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:35226–35240. DOI: https://doi.org/10.18632/oncotarget.26215.

IC50values (mean ± SD) of ribociclib, palbociclib, and abemaciclib were determined using the CyQuant cell proliferation assay. The average differential for CDK4 versus CDK6 dependent lines for ribociclib, palbociclib, and abemaciclib is 8.0-, 1.3-, and 5.5-fold, respectively. Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BC, breast cancer; CDK, cyclin-dependent kinase; DLBCL, diffuse large B-cell lymphoma; ER+, estrogen receptor-positive; IC50, half- maximal inhibitory concentration; MCL, mantle-cell lymphoma; SD, standard deviation.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27407